they are starting again with TGA because they feel it should be registered in OSLs home country.
TGA can be a great preparatory and (often) bellweather process to preceed FDA submission, but it costs time, focus and $$. Registering in any jurisdiction should have a robust business case. 'Feeling' a product should be registered in your 'home country' is a poor justification for the use of sh funds, imo.
Ann: OncoSil onboards first patient in PANCOSIL Clinical Trial, page-19
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.58M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $102 | 20.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 27827650 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29345097 | 22 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 11.1 %) |
||||
| Open | High | Low | Volume | ||
| 0.4¢ | 0.5¢ | 0.4¢ | 129546 | ||
| Last updated 11.53am 17/05/2024 ? | |||||
| OSL (ASX) Chart |